Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: A prospective study

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1537-1542

  Iwase, H ^a   Yamamoto, Y ^a   Yamamoto Ibusuki, M ^a   Murakami, K I ^a   Okumura, Y ^a   Tomita, S ^a   Inao, T ^a   Honda, Y ^b   Omoto, Y ^a   Iyama, K I ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHINYLESTRADIOL; FOLLITROPIN; PROSEXOL; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; BREAST METASTASIS; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG TREATMENT FAILURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN THERAPY; FATIGUE; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; LIVER DYSFUNCTION; LONG TERM CARE; MENOPAUSE; MUSCULOSKELETAL PAIN; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT RESPONSE; VAGINA BLEEDING; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 84884587085     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.520     Document Type: Article

References (22)

1. Agrawal A, Robertson JF, Cheung KL (2006) Efficacy and tolerability of high dose 'ethinylestradiol' in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. World J Surg Oncol 4: 44.
2. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P (1981) Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65: 179-185.
3. Bennink HJ (2008) Reprint of Are all estrogens the same? Maturitas 61: 195-201.
4. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA (2012) Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10: 821-829.
5. Cole MP, Jones CT, Todd ID (1971) A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25: 270-275.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
7. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitorresistant advanced breast cancer: A phase 2 randomized study. JAMA 302: 774-780.
8. Haddow A, Watkinson JM, Paterson E, Koller PC (1944) Influence of synthetic oestrogens on advanced malignant disease. Br Med J 2: 393-398.
9. Ingle JN (2002) Estrogen as therapy for breast cancer. Breast Cancer Res 4: 133-136.
10. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16-21.
11. Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15: 278-290.
12. Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA (2009) New hypotheses and opportunities in endocrine therapy: Amplification of oestrogen-induced apoptosis. Breast 18(Suppl 3): S10-S17.
13. Lewis JS, Osipo C, Meeke K, Jordan VC (2005) Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141.
14. Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit? Breast Cancer Res 11: 206.
15. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116.
16. Mahtani RL, Stein A, Vogel CL (2009) High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review. Clin Ther 31(Pt 2): 2371-2378.
17. Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80: 2918-2925.
18. National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5-7.pdf.
19. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence Jr J, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1): S61-S73.
20. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ (2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723.
21. Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK (2012) High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 25: 1326-1332.
22. Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, Iyama K, Iwase H (2013) Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. Mod Pathol 26: 79-86.